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ABSTRACT
Background: Colorectal cancer (CRC) is the third most common cancer in western 
countries and is driven by the Wnt signaling pathway. LIM-domain-binding protein 1 
(LDB1) interacts with the Wnt signaling pathway and has been connected to malignant 
diseases. We therefore aimed to evaluate the role of LDB1 in CRC.
Results: Overexpression of LDB1 in CRC is associated with strikingly reduced 
overall and metastasis free survival in all three independent patient cohorts. The 
expression of LDB1 positively correlates with genes involved in the Wnt signaling 
pathway (CTNNB1, AXIN2, MYC and CCND1). Overexpression of LDB1 in CRC cell lines 
induced Wnt pathway upregulation as well as increased invasivity and proliferation. 
Upon separate analysis, the role of LDB1 proved to be more prominent in proximal 
CRC, whereas distal CRC seems to be less influenced by LDB1. 
Materials and Methods: The expression of LDB1 was measured via RT-qPCR in 
59 clinical tumor and normal mucosa samples and correlated to clinical end-points. 
The role of LDB1 was examined in two additional large patient cohorts from publicly 
available microarray and RNAseq datasets. Functional characterization was done by 
lentiviral overexpression of LDB1 in CRC cell lines and TOP/FOP, proliferation and 
scratch assays. 
Conclusions: LDB1 has a strong role in CRC progression, confirmed in three large, 
independent patient cohorts. The in vitro data confirm an influence of LDB1 on the Wnt 
signaling pathway and tumor cell proliferation. LDB1 seems to have a more prominent 
role in proximal CRC, which confirms the different biology of proximal and distal CRC.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
cancer entities worldwide [1]. Survival rates are highly 
dependent on the occurrence of distant metastases [2]. 
Several signal pathways are known play a role in CRC 
development and metastasis, most prominently the Wnt 
signaling pathway, which is altered in 93% of all CRC 
tumors [3]. During the activation of the Wnt pathway, 
Wnt ligands bind to Frizzled receptors to induce the 
phosphorylation of LRP coreceptors [4]. A complex 
formed by Axin, APC, CK1α (serine/threonine kinases 
casein kinase 1 alpha) and GSK3 (glycogen synthase 
kinase 3) is recruited to the membrane and hampers the 
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ubiquitination of phosphorylated β-Catenin (CTNNB1), 
preventing its degradation [5]. β-Catenin thus accumulates 
in the cytosol and translocates into the nucleus, where it 
induces the transcription of MYC, CCND1, CD44 and 
AXIN2 genes [6–9].
LIM domain binding protein 1 (LDB1, also known 
as CLIM2 and NLI) is an ubiquitous nuclear adaptor 
protein working as a transcriptional modulator [10]. In 
mice, intrauterine knockout of Ldb1 causes severe anterior-
posterior patterning defects, including anterior truncation 
and posterior duplication, which can be partially explained 
by a downregulation of Wnt pathway antagonists [11–13]. 
In adult mice, tamoxifen-induced knockout of Ldb1 results 
in drastic changes in the small intestine including a loss 
of Lgr5+ intestinal stem cells and significant activation 
of the Wnt pathway [14]. In a chemically induced mouse 
model of hepatocellular carcinoma, hepatocyte-directed 
Ldb1 knockout lead to larger and more frequent tumors, 
which also displayed increased proliferation and resistance 
to apoptosis. Microarray and RT-PCRs  assays from tumor 
cDNA confirmed Wnt activation in Ldb1-deficient tumors 
[15]. Taken together, the currently available data indicates 
a prominent role of Ldb1 in Wnt signaling and murine 
intestinal homeostasis as well as inhibitory effects of Ldb1 
on (hepatocellular) tumorigenesis.
Despite the role of LDB1 in intestinal homeostasis 
and Wnt signaling, there is no data available on the role of 
LDB1 in CRC. We therefore aimed to evaluate the role of 
LDB1 in human CRC and investigate its molecular effects 
on colorectal tumorigenesis. To this end, we evaluated the 
expression of LDB1 in CRC patient samples and correlated 
the LDB1 expression to clinical parameters. Moreover, 
functional assays in cell lines overexpressing LDB1 were 
used to investigate the molecular effects of LDB1 in CRC.
RESULTS
High LDB1 expression in CRC is associated with 
decreased overall and metastasis-free survival
In an initial screening attempt to identify a possible 
role of LDB1 in CRC, LDB1 transcripts were measured 
in primary tumor and normal mucosa samples from 59 
CRC patients of all stages (Table 1), who underwent 
colorectal tumor resection at the Department of Surgery 
of University Hospital Heidelberg. Tumor Ct values were 
normalized to the corresponding mucosa and patients were 
separated into two groups according to a higher or lower 
expression of LDB1 in comparison with the mucosa. As 
cutoff for high LDB1 expression ΔΔCt > 0.5 was chosen, 
resulting in two cohorts of 46 and 13 patients, respectively. 
Patients were followed for a median of 30 (0–74) months.
In contrast to previous data [14, 15], high LDB1 
expression in the primary tumor was significantly 
associated with decreased overall survival (66.2 vs. 31.5 
months, Hazard Ratio (HR) = 5.86, p = 0.003) (Figure 1A) 
in our cohort of CRC patients. In order to validate these 
results, we analyzed the influence of LDB1 expression 
(measured via Affymetrix microarray) on overall survival 
in a publically available, independent cohort of 550 CRC 
patients of all stages. Overall survival was again shorter 
in tumors overexpressing LDB1 (HR = 1.5 (1.1–2.1), 
p = 0.021, Figure 1B). Further validation could be 
achieved by exploring the role of LDB1 overexpression 
in the TCGA cohort [3], in which LDB1 expression was 
measured via RNA sequencing. In this cohort (n = 267), 
LDB1 overexpression again lead to a significantly reduced 
overall survival in CRC patients of all stages (HR 2.1 
(1.0 – 4.1), p = 0.038, Supplementary Figure S1A).
To evaluate the influence of LDB1 expression on 
systemic tumor dissemination, we performed a subgroup 
analysis on patients with non-metastatic disease only. 
This analysis revealed a significantly reduced metastasis-
free survival (62.8 vs. 19.7 months, HR = 7.22, p = 0.001, 
Figure 1C) in patients with high LDB1 expression in the 
primary tumor. In the Affymetrix cohort of non-metastatic 
patients (n = 218), recurrence-free survival was also 
reduced in patients with LDB1-overexpression tumors 
(HR = 2.37 (0.97–5.78), p = 0.051, Figure 1D). The TCGA 
clinical data does not include recurrence-free survival on 
non-metastatic patients; we therefore analyzed only overall 
survival in this cohort (n = 176), which again showed 
unfavorable prognosis in LDB1-overexpressing tumors 
(HR 4.0 (1.1–13.7), p = 0.019, Supplementary Figure S1B).
In conclusion, LDB1 overexpression proved to be an 
unfavorable prognostic factor in three large, independent 
patient cohorts. LDB1 overexpression also seems to be 
strongly associated with early recurrence in non-metastatic 
patients.
Tumor LDB1 expression positively correlates 
with Wnt pathway activation in CRC patient 
samples
As LDB1 surprisingly turned out to be a negative 
prognostic factor in CRC and as LDB1 has previously 
been associated with the Wnt signaling pathway [13–15], 
we next aimed to investigate its influence on the Wnt 
signaling pathway in CRC.
To this end, the expression of LDB1 was correlated 
with the expression of the Wnt signaling-associated genes 
CTNNB1, AXIN2, MYC and CCND1 in patient primary 
tumor samples (Figure 2A). Upon direct comparison in 
patients with high or low LDB1 expression, CTNNB1 
showed a strong tendency towards overexpression 
(p = 0.11), wheres AXIN2, MYC and CCND1 were 
significantly overexpressed (p < 0.05 for all three genes) 
in LDB1-overexpressing tumors. In addition, we observed 
a highly significant positive correlation (p < 0.001 for all 
four genes) between the tumor LDB1 expression and the 
expression of Wnt signaling-associated genes (Table 2). 
This indicates a coincidence of Wnt activation and LDB1 
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Table 1: Patient characteristics
Clinicopathologic 
characteristics Total LDB1low LDB1high
N° % N° % N° %
Patients 59 100.0 46 69.5 13 30.5
Age 63.8 63.5 64.8
Gender Male 29 49.2 23 79.3 6 20.7
Female 30 50.8 23 76.7 7 23.3
Localization Colon 24 40.7 17 70.8 7 29.2
Rectum 35 59.3 29 82.9 6 17.1
UICC stage I 10 16.9 10 100.0 0 0.0
II 18 30.5 13 72.2 5 27.8
III 19 32.2 15 78.9 4 21.1
IV 12 20.3 8 66.7 4 33.3
Grade − 4 6.8 3 75.0 1 25.0
2 45 76.3 36 80.0 9 20.0
3 10 16.9 7 70.0 3 30.0
Figure 1: (A and B)  Overall survival of CRC patients with high and low LDB1 expression in the Heidelberg cohort (A, HR = 5.86, 
p = 0.003) and the Affymetrix cohort (B, HR = 1.5, p = 0.021). (C and D) Recurrence-free survival of CRC patients with high and 
low LDB1 expression in the Heidelberg cohort (C, HR = 7.22, p = 0.001) and the Affymetrix cohort (D, HR = 2.37, p = 0.051). 
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overexpression, thus explaining the negative prognostic 
value of LDB1 overexpression demonstrated in the patient 
cohorts.
Upregulation of LDB1 induces changes in MYC 
and CCND1 expression
As the positive correlation between LDB1 
expression and Wnt signaling in tumor samples was at 
least partly contradictory to previously published data 
[13–15], we aimed to investigate this interaction in 
detail. To this end, 4 human CRC cell lines (HCT116, 
DLD1, SW480, SW620) were transduced with a third 
generation lentiviral vector to generate cell lines stably 
overexpressing LDB1 (Figure 2B, Figure 3A–3D). 
The expression of LDB1 was incremented 7 to 18 fold 
in comparison to wild-type cells. The 4 cell lines were 
chosen as they represent different stages, grading and sites 
of origin of CRC manifestations.
The influence of this overexpression on Wnt signaling 
(namely the expression of Wnt signaling-associated genes 
CTNNB1, AXIN2, MYC and CCND1) was measured via 
qPCR (Figure 2B). The general trend pointed towards an 
upregulation of Wnt signaling in the LDB1-overexpressing 
cell lines; however, we also observed differential effects of 
LDB1 on the expression of Wnt signaling-associated genes. 
All cell lines overexpressing LDB1 significantly upregulated 
CCND1 transcripts; SW620LDB1-High cells showed the 
highest increase with 1.98 fold (2.21 ± 0.46 (SW620
wild-type
) 
vs. 4.37 ± 0.76 (SW620LDB1-High), p < 0.001). In 
SW480LDB1-High and SW620LDB1-High cells, MYC displayed 
an upregulation of 3.96 fold (1.37 ± 0.21 (SW480
wild-type
) 
Table 2: Correlation between tumor LDB1 expression and Wnt signaling-associated genes 
expression in CRC patients
Genes Pearson correlation p value
CTNNB1 0.471 < 0.001
AXIN2 0.465 < 0.001
MYC 0.448 < 0.001
CCND1 0.446 < 0.001
Figure 2: (A) LDB1 and Wnt pathway genes expression in CRC-patients with high vs. low LDB1 expression levels. LDB1high 
patients showed higher expression of Wnt pathway genes. (B) Expression of LDB1 and Wnt pathway genes after lentiviral LDB1 upregulation 
in CRC cell lines. Values were calculated using the 2ΔΔCt formula.  Displayed are means +/− SEM. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001.
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vs. 5.40 ± 1.69 (SW480LDB1-High), p = 0.001) and of 3.09 fold 
(1.69 ± 0.57 (SW620
wild-type
) vs. 5.21 ± 0.95 (SW620LDB1-High), 
p < 0.001) respectively. The expression of MYC in 
HCT116LDB1-High and DLD1LDB1-High cells was not significantly 
modified. Additionally, SW480LDB1-High cells produced a 
1.96 fold downregulation of CTNNB1 transcripts (1.55 
± 0.24 (SW480
wild-type
) vs. 0.79 ± 0.09 (SW480LDB1-high), 
p < 0.001) and a 1.62 fold reduction of AXIN2 (1.03 ± 
0.12 (SW480
wild-type
) vs. 0.64 ± 0.18 (SW480LDB1-high), 
p = 0.001) (Figure 2B).
Effects of LDB1 overexpression on Wnt signaling 
activity
To directly examine the stimulation of Wnt signaling 
activity by LDB1 in CRC, the previously chosen 4 CRC cell 
lines were transfected with a TCF-firefly reporter construct 
indicating Wnt signaling activity via bioluminescence 
activity. Renilla-luciferase plasmids were used to estimate 
cell viability [24]. Results are displayed in relative 
light units of luminescence (Figure 3A). DLD1LDB1-High 
and SW620LDB1-High cells exhibited a significant 
increase of Wnt signaling activity demonstrated by a 
change from 39.77 ± 4.34 to 57.57 ± 5.81 (p = 0.003) 
and 170.11 ± 12.15 to 209.44 ± 2.66 (p = 0.005) 
relative light units respectively. The Wnt signaling activity 
did not significantly change in HCT116LDB1-High and 
SW480LDB1-High cells.
Effects of LDB1 overexpression on proliferation, 
migratory potential and cell cycle
Cell proliferation was studied by counting the 
number of cells generated after an incubation time of 
72 hours (Figure 3B). The proliferation of HCT116LDB1-High 
and DLD1LDB1-High cells was significantly increased 
compared to their wild-type counterparts: Upon LDB1 
overexpression, HCT116 proliferation increased 
to 116% (7.33 x 105 ± 1.03 x 105 (HCT116
wild-type
) 
vs. 8.52 x 105 ± 0.72 x 105 (HCT116LDB1-High), 
p = 0.042). DLD1 proliferation increased to 118% (1.23 × 
106 ± 0.11 × 106 (DLD1
wild-type
) vs. 1.45 × 106 ± 0.15 × 106 
(DLD1LDB1-High), p = 0.017). Surprisingly, in SW480LDB1-High 
and SW620LDB1-High cells, the proliferation rate was 
significantly decreased. In both SW480 and SW620 LDB1 
overexpression resulted in a reduction in proliferation 
by 12% (5.37 x 105 ± 0.55 x 105 (SW480
wild-type
) vs. 
4.71 × 105 ± 0.36 x 105 (SW480LDB1-High), p = 0.035; 
9.89 × 105 ± 0.86 x 105 (SW620
wild-type
) vs. 8.68 × 105 ± 
0.87 × 105 (SW620LDB1-High), p = 0.036).
Figure 3: (A) Wnt signaling activity in cell lines overexpressing LDB1 vs. wild-type cell lines measured with TOP/FOP reporters. 
Data is shown as luminescence ratio in relative light units. (B). Proliferation of CRC cell lines after upregulation of LDB1. (C) Scratch 
assay of CRC cell lines. Results displayed as percentage of the scratch covered after 24 hours. (D). Cell cycle analysis of CRC cell lines 
overexpressing LDB1. Displayed are means +/− SEM. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001.
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As we observed increased metastatic activity of 
LDB1-overexpressing tumors, we next aimed to assess 
the invasiveness of cells overexpressing LDB1 in a 
wound healing assay. A scratch was made on the surface 
of 6-well plates and the width of this lane was measured 
immediately and after 24 hours. Results are expressed 
in percentage of the lane covered by cells (Figure 3C). 
HCT116LDB1-High and DLD1LDB1-High did not show significant 
changes in their invasivity (53.04% ± 9.24% 
(HCT116
wild-type
) vs. 48.86% ± 6.02% (HCT116LDB1-High), 
p = 0.375; 36.00% ± 8.57% (DLD1
wild-type
) vs. 33.63% ± 
5.33%  (DLD1LDB1-High), p = 0.578). In SW480LDB1-High the 
covered space was slightly increased (19.53% ± 5.30% 
(SW480
wild-type
) vs. 23.59% ± 5.38% (SW480LDB1-High), 
p = 0.218); in SW620LDB1-High the invasivity was 
significantly increased (6.29% ± 2.13% (SW620
wild-type
) vs. 
10.16% ± 3.30% (SW620LDB1-High), p = 0.036).
To investigate the effects of LDB1 overexpression 
on cell cycle regulation, the cell cycle phases of CRC 
cell lines were analyzed via flow cytometry (Figure 3C). 
HCT116LDB1-High and SW480LDB1-High cells did not show 
major differences in comparison with wild-type cells. 
DLD1LDB1-High cells displayed a significant increase of 
cells in G0/G1 phase from 64.04% to 69.72% (p = 0.025), 
indicating an increased number of cells entering 
proliferation and thus confirming the results of the 
proliferation assays. This change simultaneously reduced 
the number of cells in G2/M from 17.73% to 13.64% (p 
= 0.010). Apoptotic cells decreased from 3.43% to 1.83% 
(p = 0.144) and cells in S phase remained constant at 14% 
(p = 0.992). In SW620LDB1-High cells, apoptosis augmented 
from 2.82% to 7.14% (p = 0.029), the G0/G1 phase was 
reduced from 57.35% to 12.45% (p < 0.001) and the S 
phase changed from 20.05% to 7.77% (p < 0.001). The 
G2/M phase increased from 19.78% to 72.64% (p < 0.001), 
indicating an arrest of these cells before mitosis. This 
observation again confirms the results of the proliferation 
assays.
LDB1 may have different roles in tumors of the 
proximal and distal colorectum
During embryologic development, the colorectum 
is formed by two primordial organs, the midgut and the 
hindgut. The point of fusion is the left colic flexure (Cannon-
Böhm’s point), where the blood supply switches from the 
superior mesenteric artery to the inferior mesenteric artery. 
Multiple studies are currently investigating molecular 
differences between tumors of the proximal colon (proximal 
to the left colic flexure) and distal colon (distal to the left 
colic flexure down to the anal verge). Little is known so far; 
however, the currently available data indicates that proximal 
and distal tumors are in fact entirely different entities 
[28–30]. Interestingly, recent data suggests that the proximal 
colon is more susceptible to Wnt associated tumorigenesis, 
which results in tumor formation upon moderate Wnt 
activation. This increased susceptibility distinguishes 
the proximal from the distal colon, which requires more 
pronounced Wnt activation in order to result in tumor 
formation [31, 32]. As we have demonstrated the role of 
LDB1 in Wnt signaling and have also observed differential 
effects of LDB1 on CRC proliferation and invasiveness, 
we hypothesized that the role of LDB1 may differ between 
tumors of different locations within the colorectum.
We therefore analyzed the Affymetrix cohort 
according to tumor localization (Figure 4). The effects 
of LDB1 were more pronounced in the subgroup with 
tumors in the proximal tumor than in the subgroup with 
distal CRC (OS: HR = 1.69, p = 0.14 (proximal) vs. HR 
= 1.27, p = 0.35 (distal); RFS: HR = 1.7, p = 0.0076 
(proximal) vs. HR = 1.35, p = 0.064 (distal)). Stratified 
analyses based on tumor location were not possible in 
the Heidelberg patient cohort due to low case numbers. 
We also evaluate the influence of LDB1 on recurrence-
free survival in non-metastatic patients according to 
tumor localization and again observed a striking effect 
of LDB1 in the proximal colon; in this cohort (n = 45) 
no recurrences were observed in patients with low LDB1 
expression (Figure 4E and 4F).
After splitting the patient samples due to 
localization, the association between tumor LDB1 
expression and Wnt pathway gene expression remained 
significant for almost all genes analyzed in samples from 
the proximal colon and for all genes in samples derived 
from the distal colon (Table 3A). In samples from the 
proximal colon, the association between LDB1 expression 
on Wnt signaling-associated genes seemed generally to be 
even stronger than in distal tumors; however, due to the 
relatively low case number (due to the lower incidence of 
proximal CRC) significance levels were lower. We also 
hypothesized that as the rectum is the most distal segment 
of the colon, the effects of LDB1 in the rectum may be 
even less pronounced. We therefore also performed an 
analysis after splitting our cohort in patients with tumors 
in the colon vs. the rectum. In this analysis, association 
between tumor LDB1 expression and Wnt pathway gene 
expression remained significant for samples derived from 
the colon, but not for samples derived from the rectum 
(Table 3B), again stressing the increased effects of LDB1 
in the proximal colon as opposed to the distal colorectum.
DISCUSSION
CRC is among the most commonly investigated 
tumor entities [2, 17, 33, 34]. The most prominent 
signaling pathway in CRC is Wnt signaling, its activation 
(most frequently by inactivating APC mutations) 
usually initiates the adenoma-carcinoma sequence and 
thus colorectal tumorigenesis [35]. Previous data from 
mouse models demonstrated a prominent role of Ldb1 
in hepatocellular carcinoma and intestinal homeostasis, 
indicated an inhibition of Wnt signaling by Ldb1 and 
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hence a tumorsuppressive role of Ldb1 overexpression 
[14, 15]. As the majority of CRCs are heavily dependent 
on Wnt signaling, we hypothesized that LDB1 may have 
a role in human CRC as well. More precisely, we aimed 
to show the role of LDB1 as a tumor suppressor in CRC.
Unsurprisingly, the expression of LDB1 in our 
patients proved to be heterogeneous. Surprisingly, 
however, patients with lower LDB1 expression in the 
tumor experienced improved overall and metastasis-free 
survival, thus demonstrating a negative prognostic effect 
of LDB1 expression in human CRC. These results could be 
reproduced in two independent, large cohorts of patients 
(Affymetrix and TCGA samples), therefore strongly 
validating our results. In addition, qPCR expression 
profiling showed higher expression levels of CTNNB1, 
AXIN2, MYC and CCND1 in patients with LDB1 
Figure 4: Comparison of survival and recurrence rates depending on tumor location proximal (graphs on left side) and 
distal to the left colic flexure (graphs on right side).  CRC patients of all stages with tumors located in the proximal colon and high 
expression of LDB1 showed a tendency to shorter overall survival (A, HR 1.69, p = 0.14) and significantly shorter recurrence-free survival 
(C, HR = 1.7, p = 0.0076). LDB1lowPatients with non-metastatic (M0) CRC in the proximal colon showed a strikingly improved recurrence 
free survival with no recorded recurrences in the study cohort (E, HR not calculable, p = 0.038). The effects of LDB1 seem to be much less 
pronounced in the distal colon; overall survival rates of distal CRC patients are similar for LDB1high and LDB1low patients (B, HR = 1.27, 
p = 0.35). The effects of LDB1 expression on recurrence-free survival are also less pronounced in patients with distal CRC (D, HR = 1.35, 
p = 0.064). In patients with non-metastatic distal CRC, LDB1 overexpression leads to reduced recurrence-free survival, albeit to a lesser 
extent than in the proximal colon (F, HR = 3.7, p = 0.016). 
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overexpression, suggesting an increased Wnt signaling 
activity in these tumors and supporting the clinical data 
reported above. 
These findings are in contradiction to previous data 
[13–15], which indicated a suppressive effect of Ldb1 on 
the Wnt signaling pathway. However, these data were from 
mouse models only; it is conceivable that murine Ldb1 has 
different effects and targets than human LDB1. Another 
explanation of the contradictory results of many studies 
on Ldb1 may be organspecific effects of Ldb1: While 
inactivation of Ldb1 led to an increase in tumor growth in 
murine hepatocellular carcinoma [15], its overexpression 
in mammary glands promoted breast tumorigenesis [36, 
37]. In addition, widespread LDB1 expression has been 
demonstrated in embryonic epithelial tissues [38, 39] 
and at the invasive front of squamous cell carcinoma of 
the head and neck [40], preventing differentiation of 
LDB1-overexpressing cells and again suggesting tumor-
promoting effects of LDB1. These findings strongly 
suggest organ-specific effects of Ldb1 and further support 
our data identifying LDB1 as a negative prognostic factor 
in CRC.
To further validate LDB1 as a tumor-promoting 
factor in CRC, we initiated a series of in vitro experiments 
using lentiviral vectors to overexpress LDB1 in human 
CRC cell lines. We observed differential effects; however, 
most results again pointed towards an activation of the 
Wnt signaling pathway in human CRC, supporting the 
results seen in patient samples. Interestingly, the 4 genes 
we used as indicators of Wnt signaling activity were 
not uniformly regulated upon LDB1 overexpression, 
indicating incomplete activation of the Wnt signaling 
pathway, which has recently be described in other tumor 
entities and transcription factors as well [41].
There are currently no studies available investigating 
the correlation of LDB1 overexpression with metastatic 
activity; however, LDB1 overexpression at the invasive 
front of squamous cell carcinomas of the head and neck 
suggests a connection between LDB1 overexpression 
and metastasis [40]. In the present study, patients with 
LDB1 overexpression in the tumor tissue displayed worse 
overall survival and metastasis-free survival. These results 
indicate that CRC tumors with low expression of LDB1 
metastasized later than tumors with a higher expression, 
indicating pro-metastatic features of LDB1 in CRC. This 
finding was also supported by the other two clinical 
cohorts and is well in line with above mentioned data from 
human SCC of the head and neck [40].
Colorectal cancer is usually classified as a single 
entity despite data showing distinct molecular, pathological 
and clinical features of proximal and distal colon cancers 
[28–30]. This differentiation is embryologically well 
justified as the colorectum develops from both the 
midgut (ascending and transverse colon) and the hindgut 
Table 3: Correlation between tumor LDB1 expression and Wnt signaling-associated genes 
expression in CRC patients
A. Location Parameter CTNNB1 AXIN2 MYC CCND1
All samples
Pearson correlation 0.471 0.465 0.448 0.446
p value < 0.001 < 0.001 < 0.001 < 0.001
Proximal
Pearson correlation 0.493 0.766 0.709 0.538
p value 0.147 0.010 0.022 0.109
Distal
Pearson correlation 0.447 0.485 0.410 0.460
p value 0.001 < 0.001 0.003 0.001
B. Location Parameter CTNNB1 AXIN2 MYC CCND1
All samples
Pearson correlation 0.471 0.465 0.448 0.446
p value < 0.001 < 0.001 < 0.001 < 0.001
Colon
Pearson correlation 0.636 0.739 0.659 0.766
p value 0.001 < 0.001 < 0.001 < 0.001
Rectum
Pearson correlation 0.322 0.273 0.274 0.171
p value 0.059 0.113 0.112 0.326
AProximal and distal samples were analyzed separately. 
BColon and rectum samples were analyzed separately.
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(descending and sigmoid colon and rectum). Above 
mentioned studies demonstrated increased activation of 
the Wnt pathway and MYC expression in distal colorectal 
carcinomas in comparison with proximal tumors. Given 
this differential role of Wnt signaling in CRC and the 
effects of LDB1 overexpression on Wnt signaling, we 
hypothesized that the role of LDB1 may be different in 
proximal and distal CRC. We therefore analyzed the 
clinical data of our patient cohort as well as previously 
published patients according to the location of the tumors 
and were able to demonstrate a larger effect of LDB1 
overexpression in proximal CRC compared to distal CRC. 
In addition, the association between LDB1 expression 
and Wnt signaling activity was stronger in tumors of 
the colon than rectal tumors. These differential roles of 
LDB1 according to tumor location may be explained by 
the varying levels of Wnt activity on proximal and distal 
CRC: Proximal carcinomas upregulate the Wnt pathway 
to a lesser extent than distal tumors; therefore, LDB1 may 
upregulate Wnt in proximal tumors more easily than in 
distal tumors, which already exhibit high Wnt signaling 
activity. The relatively increased expression of Wnt 
pathway genes in the LDB1-overexpressing, proximal 
(colon) cancer samples analyzed here may be a result 
of the higher LDB1 expression; this in turn can explain 
the increased clinical effects of LDB1 overexpression in 
proximal CRC samples.
To study the influence of LDB1 on malignant 
features such as proliferation, invasiveness and cell cycle 
dysregulation, HCT116, DLD1, SW480 and SW620 
cells were infected with a third generation lentivirus to 
overexpress LDB1. Although the gene expression and 
phenotypic changes after the upregulation of LDB1 did 
not show a unique pattern, it was possible to recognize 
that HCT116LDB1-High and DLD1LDB1-High cells developed 
a similar phenotype with increased proliferation and 
augmented the expression of CCND1. SW480LDB1-High 
and SW620LDB1-High cells constituted a second phenotype, 
exhibited an upregulation of Wnt pathway genes including 
a marked overexpression of MYC, reduced proliferation 
rate and increased invasivity. 
Generally, the Wnt signaling activity on proximal 
colon tumors is lower compared to the Wnt signaling 
activity in distal colon tumors [31, 32]. The site of origin 
(proximal vs. distal colon) of the cell lines is unknown; 
however, based on the Wnt signaling activity they may 
correspond to proximal (group 1) and distal colon (group 
2). The overexpression of LDB1 resulted in an increase in 
proliferation and Wnt signaling activity in group 1, while 
it reduced the proliferation in group 2. This supports 
our clinical findings, indicating a greater role of LDB1 
overexpression in tumors of the proximal colon. On 
the other hand, LDB1 overexpression also has an effect 
in distal CRC, albeit weaker. In addition to decreased 
proliferation, the effects of LDB1 overexpression on the 
group 2 cell lines included increased invasiveness which 
may partly explain the clinical findings.
In conclusion, LDB1 overexpression is a negative 
prognostic factor in colorectal cancer. Its effects are 
stronger in tumors of the proximal colon, which may 
be due to comparatively low intrinsic Wnt signaling 
activity in these tumors which is stimulated by LDB1 
overexpression. In vitro, LDB1 overexpression has 
differential effects on human CRC cell lines, which is 
again dependent on their intrinsic Wnt activity. Limitations 
of this study include its retrospective nature. However, 
the clear prognostic effects of LDB1 overexpression 
demonstrated in this work clearly indicate the need 
for further studies. Given the unclear role of adjuvant 
treatment in stage II CRC patients and the prognostic 
value of LDB1 regarding the prediction of metastasis, a 
prospective study in stage II CRC may establish LDB1 as 
a valuable biomarker in nonmetastatic CRC.
MATERIALS AND METHODS
Patient samples
Clinical data and samples are being collected 
continuously at the Department of Surgery of University 
Hospital Heidelberg; our management of patients with 
colorectal cancer has been published in detail before [16, 17]. 
Tumor and mucosa samples were collected from 59 
CRC patients (of all UICC stages), which underwent 
tumor resection at the Department of General, Visceral 
and Transplantation Surgery at the University Hospital 
in Heidelberg between October 2006 and July 2012. The 
study was approved by the independent ethics committee of 
the University of Heidelberg. All patients provided written 
informed consent prior to surgery. This patient cohort is 
henceforth referred to as the Heidelberg cohort.
Affymetrix CRC cohort
A database of publicly available colorectal cancer 
patient samples measured by Affymetrix gene chips was set 
up as described previously for gastric cancer [18]. In brief, 
gene chip datasets with transcriptome-wide gene expression 
data generated by Affymetrix gene arrays and available 
survival data were identified in the Gene Expression 
Omnibus repository (www.ncbi.nlm.nih.gov/geo/). 
Samples were MAS5 normalized. We selected the probe 
set 35160_at for LDB1. Survival analysis was performed 
by employing Cox proportional hazard regression in the 
R statistical environment (www.r-project.org) as described 
previously [19]. Kaplan–Meier survival plot, and the 
hazard ratio with 95% confidence intervals and log-rank 
P value were plotted using the library “survival”.
TCGA CRC cohort
Colorectal cancer patients measured by RNA-seq 
were published in The Cancer Genome Atlas (TCGA) [3]. 
Pre-processed level 3 data generated using Illumina HiSeq 
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2000 RNA Sequencing V2 was used. For each sample, the 
expression level was determined using a combination of 
MapSplice and RSEM. The individual sample files were 
merged in R using the plyr package [20]. Survival analysis 
was performed as for the Affymetrix cohort.
Cell culture
CRC cell lines were obtained from ATCC (HCT116, 
DLD1, SW480, SW620) and cultured at 37ºC with 5% 
CO2 and 95% humidity. DMEM (Thermo Fisher, Waltham, 
USA) and RPMI (Thermo Fisher, Waltham, USA) media 
were supplemented with 10% fetal bovine serum (FBS) 
(Thermo Fisher, Waltham, USA) and no antibiotics were 
used. Cell lines were regularly screened for Mycoplasma 
contamination; the cell line authenticity was confirmed 
regularly.
LDB1 overexpression
Cell lines constitutively overexpressing LDB1 were 
generated by transduction with a third generation lentiviral 
vector system [21]. For virus production, HEK293T 
cells were cultured in DMEM medium with 10 % heat 
inactivated FBS. A mixture of 3 mL OptiMEM® (Thermo 
Fisher, Waltham, USA) medium, 28 μL Lipofectamin® 
2000 (Thermo Fisher, Waltham, USA), 4 μg pMDLg/
pRRE (was a gift from Didier Trono, Addgene plasmid 
# 12251), 2 μg pRSVRev (Addgene plasmid # 12253), 
2 μg pMD2.G (Addgene plasmid # 12259) and 6 μg EX-
Z6214-Lv205 (GeneCopoeia, Rockville, USA) was added 
dropwise to transfect HEK293T cells. After 24 hours, 
medium was replaced with fresh medium and incubated 
for another 24 hours. The virus-enriched medium was 
collected, filtered and mixed with polybrene (8 μg/mL final 
concentration). 1 × 105 cells from each CRC cell line were 
seeded per well on 6-well plates and incubated with the 
virus solution for seven hours. After 48 hours, transduced 
cells were selected with puromycin (final concentration 
10 μg/mL). To select brightly GFP expressing cells, 
CRC cell lines were sorted with a FACS ARIA II (BD 
Biosciences, San Jose, USA). Sorted cells were grown in 
medium with 10% FBS and 1% penicillin/streptomycin. 
Control cell lines were generated similarly using a 
modified version of the EXZ6214Lv205 vector, lacking 
the LDB1 gene.
Plasmid amplification
One Shot® TOP10 chemically competent E. coli 
cells (Thermo Fisher, Waltham, USA) were transformed 
following the manufacturer’s instructions, adding 2 μL 
from the corresponding plasmids. Plasmid DNA was 
isolated with the Qiagen EndoFree® Maxi Kit (Qiagen, 
Hilden, Germany), following the manufacturer’s 
protocol. DNA was eluted with nuclease-free water and 
concentration was adjusted to reach 1 μg/μL.
RNA isolation
Tissue samples were fragmented using the 
TissueLyser II (Qiagen, Hilden, Germany). The 
NucleoSpin® RNA Kit (Macherey-Nagel, Düren, 
Germany) was used for RNA isolation following the 
manufacturer’s instructions. Tissue fragments were 
inserted into microcentrifuge tubes containing 700 µL 
buffer RA1 and one 5 mm stainless steel bead (Qiagen, 
Hilden, Germany). Samples were shaken twice at 30 Hz 
for 2 minutes. Cell lines pellets were lysed with 350 µL 
buffer RA1. RNA was eluted with 40 µL RNAase-free 
water and concentration was measured using a NanoVue™ 
Plus Spectrophotometer (GE Healthcare, Piscataway, 
USA).
cDNA synthesis
The High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher, Waltham, USA) was used for cDNA 
synthesis. For each reaction, 1 µg of RNA was mixed 
with 2 µL RT Buffer, 2 µL RT random primers, 0.8 µL 
dNTP Mix, 1 µL MultiScribe™ Reverse Transcriptase 
and RNAase-free water to complete 20 µL. Tubes were 
incubated in a thermocycler at 25ºC for 10 minutes, at 
37ºC for 120 minutes and at 85ºC for 5 minutes. Tissue 
samples were diluted with Nuclease-free water in a 1:5 
ratio and cell lines in a 1:10 ratio.
Quantitative PCRs
Methods have been described before [22, 23]. 
Briefly, quantitative PCRs were performed using the 
StepOnePlus™ RealTime PCR System (Thermo Fisher, 
Waltham, USA). One reaction consisted in 2.5 µL cDNA, 
5 µL Power SYBR® Green PCR Master Mix (Thermo 
Fisher, Waltham, USA), 0.5 µL from each 5 µM primer 
(forward and reverse) and 1.5 µL RNAase-free water. The 
following primers were designed using Primer3Plus (5′ 
to 3′): GAPDH_fwd GACCCCTTCATTGACCTCAAC; 
GAPDH_rev TTGATTTTGGAGGGATCTCG; LDB1_fwd 
 TGTATCCGCCTACATACCTG; LDB1_rev TGGTCAA 
CATGGCATCATCC; CTNNB1_fwd TTCCGAATGT 
CTGAGGACAAG; CTNNB1_rev TGGGCACCAA 
TATCAAGTCC; AXIN2_fwd TGGCTATGTCTTT 
GCACCAG; AXIN2_rev TGTTTCTTACTGCCCACACG; 
MYC_fwd TGCTCCATGAGGAGACACC; MYC_rev 
GATCCAGACTCTGACCTTTTGC; CCND1_fwd TCCT 
CTCCAGAGTGATCAAGTG; CCND1_rev TTGGGG 
TCCATGTTCTGC. Holding stage was set at 50ºC for 
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2 minutes and at 95ºC for 10 minutes. Cycling stage at 
95ºC for 30 seconds and at 60ºC for 1 minute repeated 
40 times. Melt curve stage was set at 95ºC for 15 seconds 
and ramp with an 0.2ºC increase from 65ºC to 97ºC. 
Cycle thresholds (Ct) values were calculated using the 
AB StepOne™ v2.1 software (Thermo Fisher, Waltham, 
USA). Tissue Ct values were first normalized to GAPDH 
and then to mucosa using the ΔΔCt equation:
∆∆Ct CtGAPDHTumor Ct target gene Tumor
CtGAPDH Mucos
= −( ) −� � � � � �
� � a Ct target geneMucosa−( )� � � �
Ct values from cell lines were normalized to 
GAPDH. The fold change of these genes was calculated 
using the 2ΔCt equation.
2 2∆Ct Ct GAPDH Ct target gene= −(  )
Genetic modified CRC cell lines were first 
normalized to GAPDH and then normalized with the 
wildtype cell lines, using the following equation:
2 2∆∆Ct
Ct GAPDH modified cells Ct target modified cells
=
−( � � � � � � � � ) −
−( )
�
� � � � � � � � �Ct GAPDH wildtype cells Ct target wildtype cells
Cell proliferation
Cell lines were seeded onto 24-well plates and 
incubated for three days at 37ºC with 5% CO2 and 95% 
humidity. Cells were then trypsinized and resuspended in 
1 mL of medium. Ten microliters from the cell suspension 
were pipetted per pocket into counting slides. Cells were 
counted with an automatic cell-counter.
TOP/FOP functional Wnt activation assay 
Ten to twenty thousand cells were seeded per well 
onto 96-well plates. After 24 hours’ incubation, cells were 
transfected (per well) with 19.6 µL OptiMEM® (Thermo 
Fisher, Waltham, USA), 0.2 µL Lipofectamin®2000 
(Thermo Fisher, Waltham, USA), 10 ηg Renilla plasmid 
[24] and 100 ηg TOP or FOP plasmids [25, 26]. Plates 
were incubated overnight at 37°C. Luminescence 
produced by Firefly and Renilla luciferase was measured 
with a Tecan GENios spectrophotometer (Tecan, 
Männedorf, Switzerland) using the DualGlo® Luciferase 
Assay System (Promega, Madison, USA). Firefly was first 
normalized to Renilla and then the ratio between TOP and 
FOP was calculated.
Cell cycle analysis
General flow cytometry methods of our group have 
been published in detail before [27]. Briefly, cells were 
seeded onto 24-well plates. After three days in culture, 
supernatant and cells were collected into flow cytometry 
tubes. Pellets were resuspended with 1 mL ice-cold 70% 
ethanol and incubated at 4°C overnight. Samples were 
centrifuged and cells were washed twice with 1 mL PBS. 
To digest RNA, each pellet was incubated with 100 µL 
of 0.2 mg/mL RNase A solution (Sigma-Aldrich, St 
Louis, USA) at 37°C for 1 hour. Cells were incubated 
with 10 µL 1 mg/mL Propidium Iodide (Sigma-Aldrich, 
St Louis, USA). Flow cytometry was performed with the 
BD FACSCalibur™ (BD Biosciences, San Jose, USA). 
In total 10,000 events were counted per cell sample. Cell 
counts were analyzed with the WinMDI 2.9 software (The 
Scripps Research Institute, La Jolla, USA) to determine 
the percentage of cells per cell cycle phase.
Scratch assay
One to two million cells were seeded per well onto 
6-well plates. After 24 hours, scratches were made on 
each well with a 100 µl pipet tip. Perpendicular lines were 
marked bellow the bottom of the plate to determinate a 
specific place. Pictures were made after 24 hours with 
a Leica DMI3000B microscope (Leica Microsystems, 
Wetzlar, Germany) using the Leica Application Suite 
v3.6 software (Leica Microsystems, Wetzlar, Germany). 
The distance between the two edges was measured and 
shortening was calculated using the same software.
Statistical analysis
Survival/recurrence rates were depicted using 
Kaplan-Meier curves and compared using the log-rank 
test. Results from in vitro experiments were compared 
using the Student’s independent samples t-test (to compare 
means) and bivariate correlation (Pearson correlation). 
P values < 0.05 were considered statistically significant. 
The following code was used in this article to display 
significance levels: (*) p < 0.05, (**) p < 0.01, (***) 
p < 0.001.
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